What is the recommended dose and intramuscular route for hepatitis B vaccine?

Hepatitis B Vaccine Dose and Route

Hepatitis B vaccine should be administered intramuscularly in the deltoid muscle (or anterolateral thigh in infants) using age-specific doses: 10 mcg (0.5 mL) for infants/children/adolescents aged <20 years, and 20 mcg (1.0 mL) for adults ≥20 years, given as a 3-dose series at 0,1, and 6 months. 1, 2, 1

Age-Specific Dosing

Infants and Children (<1 to 10 years)

• Dose: 10 mcg (0.5 mL) 2
• Route: Intramuscular in anterolateral thigh (infants) or deltoid (children)
• Schedule: 0,1,6 months or 0,2,4,6 months (with combination vaccines) 1

Adolescents (11-19 years)

• Standard regimen: 10 mcg (0.5 mL) at 0,1,6 months 2
• Alternative for ages 11-15: 20 mcg (1.0 mL) adult formulation as 2-dose series at 0 and 4-6 months (Recombivax HB only) 2, 3

Adults (≥20 years)

• Dose: 20 mcg (1.0 mL) 2
• Route: Intramuscular in deltoid muscle
• Schedule: 0,1,6 months (standard) or 0,1,4 months or 0,2,4 months (alternative schedules acceptable) 1, 4

Special Populations

Hemodialysis patients and immunocompromised adults (≥20 years):

• Dose: 40 mcg (two 20 mcg doses or dialysis formulation) 2
• Schedule: 0,1,2,6 months (4-dose series) 1
• Monitoring: Annual anti-HBs testing; booster when <10 mIU/mL 1

Route of Administration

Intramuscular (Standard and Recommended)

The intramuscular route is the only recommended route for routine hepatitis B vaccination 5. The evidence strongly supports this:

• Site selection: Deltoid muscle in adults, adolescents, and older children; anterolateral thigh in infants and young children 6
• Needle size: 5/8-inch, 25-gauge for toddlers/children; 1-inch, 23-gauge for older children and adults 6
• Immunogenicity: IM administration produces significantly higher seroconversion rates (97.2% vs 78.1%) and geometric mean titers (1649 vs 126 IU/L) compared to intradermal route 7

Subcutaneous (Only for Specific Bleeding Disorders)

• Indication: Reserved exclusively for persons at risk of hemorrhage (e.g., hemophiliacs) 6
• Caveat: Results in lower GMTs and increased risk of local reactions including subcutaneous nodules 6
• Clinical implication: This is a compromise for safety, not an equivalent alternative

Intradermal Route (NOT Recommended)

While older research explored intradermal administration with reduced doses (2 mcg), this route is not recommended in current guidelines 1. The evidence shows:

• Lower seroconversion rates 7
• Significantly lower antibody titers 7, 8
• Persistent induration and hyperpigmentation at injection sites 9
• Failed to boost antibody in previously vaccinated individuals 7

Critical Scheduling Details

Minimum Intervals (When Series is Interrupted)

• Between doses 1 and 2: Minimum 4 weeks 1
• Between doses 2 and 3: Minimum 8 weeks 1
• Between doses 1 and 3: Minimum 16 weeks 1
• Final dose in infants: Not before 24 weeks of age 1

Important: If the series is interrupted, do NOT restart—simply continue with the next dose as soon as possible 1

Grace Period

Doses administered ≤4 days before the minimum interval are considered valid 1. Exception: This grace period does NOT apply to the accelerated Twinrix schedule (0,7,21-30 days, 12 months) 1

Newer Vaccine Options (Adults ≥18 years)

Heplisav-B

• Dose: 20 mcg (0.5 mL) 2, 3
• Schedule: 2-dose series at 0 and 1 month 2, 3
• Advantage: Faster completion, higher seroprotection rates (90% vs 70.5-90.2% with Engerix-B) 2
• Limitation: Not approved for use in persons <18 years, hemodialysis patients, or pregnant women 2, 3

PreHevbrio (ACIP-recommended 2022)

• Dose: 10 mcg (1.0 mL) 3
• Schedule: 3-dose series at 0,1,6 months 3
• Note: Three-antigen formulation; not for hemodialysis patients or pregnant women 3

Common Pitfalls to Avoid

1. Wrong injection site: Gluteal administration results in lower immunogenicity—always use deltoid in adults 6
2. Subcutaneous administration in non-bleeding disorders: This compromises immune response 6
3. Restarting interrupted series: Never necessary; just continue where left off 1
4. Using combination vaccines for birth dose: Only single-antigen vaccine can be used at birth; Comvax and Pediarix cannot be given before 6 weeks of age 5
5. Inadequate needle length: Ensure proper IM delivery, especially in obese patients (obesity reduces seroprotection) 10

Product Interchangeability

Different manufacturers' vaccines can be used interchangeably to complete the series without compromising immunogenicity 1. However, whenever feasible, use the same vaccine brand throughout the series 1.